Positive data for Eylea in branch form of occlusion

Share this article:
On Monday Regeneron reported more positive data for its wet AMD/macular edema drug Eylea (aflibercept). This time, it's in patients with macular edema following branch retinal vein occlusion (BRVO), a potentially blinding retinal disorder caused by a blockage in the blood vessels branching from the main vein draining the retina.

The biotech, which said it intends to submit a regulatory application for marketing approval for a possible BRVO indication in the US within the next several months, added that the Phase III trial was the eighth positive one for Eylea.

Regeneron was already prepping an NDA submission for diabetic macula edema (DME), while its European marketing partner, Bayer, is on track to do the same abroad. Roche's wet AMD drug Lucentis already has DME on its label.

As FiercePharma pointed out, Eylea's two existing indications—wet AMD and for macular edema following central retinal vein occlusion (CRVO)—generated US revenue of $643.7 million in the first half of this year, with some of that going to ex-US marketing partner Bayer.

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Payment database confounds doctors

ProPublica reports that doctors are struggling with a time-intensive registration process and are getting an error message that CMS says is not an error message.

Gilead's idelalisib hat trick

The FDA greenlighted the drug for three cancers.

Shire expands rare disease reach

A $225-million deal with US biotech ArmaGen gives Shire worldwide commercialization rights to an experimental enzyme replacement therapy.